> I don't really see improvement during weekday service from track work

Tracks wear out, you know? The improvement is that the trains are still running

Great, that's done. Now fine him for the mayor infestation at the same address

They didn't even do amyloid PET. There are a long list of disorders that cause neurodegeneration in young adults and don't involve AD pathology.

Santos is really turning into the most entertaining story of 2023. He's had a more interesting life than the next 20 people put together.

Yew want to know what the reel horror is, hey? Wal, it’s this—it ain’t what them fish devils hez done, but what they’re a-goin’ to do! They’re a-bringin’ things up aout o’ whar they come from into the taown—ben doin’ it fer years, an’ slackenin’ up lately. Them haouses north o’ the river betwixt Water an’ Main Streets is full of ’em—them devils an’ what they brung—an’ when they git ready. . . . I say, when they git ready . . . ever hear tell of a shoggoth?

Most physicians wouldn't characterize catheter ablation as 'surgery', nor does the source NEJM article use that term, preferring 'ablation'. It's an interventional procedure done by a cardiologist via a catheter in the femoral or radial artery.

The properly-called "surgical" treatment for a-fib is Cox's MAZE procedure, which has undergone several modifications over the years and is sometimes called pulmonary vein isolation. It involves opening the chest and making a series of precise cuts in the back wall of the left atrium, then sewing it back up. It's usually - I dare say almost always - performed only when the surgeon is already in the chest for some other reason, such as surgical correction of mitral valve stenosis.

TL;DR: We've been fooling with this molecule for nearly 50 years and haven't found a single thing it's good for, but every 3 months we'll publish a review suggesting it should be tried on whatever disease is flavor-of-the-month.

The downside of this method - popularly called 'market timing' - is that you can lock yourself out of gains if you get it wrong. The conventional wisdom is that "Time in the market beats timing the market."

I am a neurologist. People do indeed die screaming on the cancer ward, happens all the time. My point was just that it's a little odd to find these details in a science journal article about an investigational drug.

I have rarely seen such a dramatized account of a medical complication in a science journal, by the way. When folks die in cancer trials, is it commonplace to describe their screaming, or the visit of the priest to the bedside?

From the Science artice you linked:

>Still, one reason to think lecanemab contributed to the woman’s death is that her autopsy revealed widespread cerebral amyloid angiopathy (CAA), a condition in which amyloid deposits gradually replace the smooth muscle of blood vessel walls. Castellani, Nicoll, and others who reviewed her case suspect CAA made her blood vessels vulnerable to weakening when lecanemab did what it is expected to do: strip amyloids from the brain. The tPA treatment then likely ruptured those weakened vessels, leading to serious ARIA—and apparently fatal brain bleeding, according to the Northwestern report authors and independent CAA or Alzheimer’s experts.

What the article doesn't mention is that CAA would be a contraindication to t-PA therapy for stroke, whether someone had received anti-amyloid therapy or not.

Considering t-PA therapy for stroke is always a "chaotic scene" because there is a brief window of time after stroke onset that it can be used, and the standard imaging studies used to see if t-PA is indicated don't detect CAA - you have to look back in the record and see if an MRI has been done, and that lookback isn't always possible in the emergency department setting.

People receive therapies for incurable cancers that have far worse side effects. AD is an incurable, terminal disease and some folks would be able to use the extra time this treatment provides.

That's no good, it might improve the water quality.